** Vigil Neuroscience shares VIGL.O jump 245% to $8 premarket as Sanofi to acquire firm in $470 million deal to boost its neurological pipeline
** Sanofi would pay $8 per share to Vigil shareholders, who would also be eligible for a contingent value right $(CVR)$ of $2 per share
** CVR is tied to a drug that Vigil is developing for the potential treatment of Alzheimer's disease
** Shares of Vigil, which have lost a third of their value in the past 12 months, closed at a valuation of about $100 mln on Wednesday
(Reporting by Medha Singh)
((medha.singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.